Crohn’s disease is a chronic inflammatory bowel syndrome that causes inflammation in the gastrointestinal tract. Inflammation can take place anywhere between mouth to anus. It commonly affects end of small intestine (Ileum) and beginning of the colon. Common symptoms of Crohn’s disease from mild to severe intensity include abdominal pain, frequent diarrhea, reduced appetite, and fever. Sometimes rectal bleeding is also observed due to fissures from inflammation at anal canal. Factors responsible for development of Crohn’s disease include hereditary genes, autoimmune reaction that causes inflammatory condition, and environmental factors such as bacteria and virus. It is observed that smokers are more vulnerable to Crohn’s disease.
Crohn’s disease commonly affects the age group of 15 - 35 years. It is diagnosed with blood test and medical imaging techniques. Management of Crohn’s disease includes lifestyle modification, medications, and surgery.
U.S. and Europe to drive the growth of Crohn’s disease treatment market due to high incidence and prevalence
The U.S. and Europe have high incidence of Crohn’s disease, which is expected to drive the growth of market. According to a study published in the Lancet in October, 2017, around 319 (U.S.) and around 322 (Europe) cases of Crohn’s disease per 1, 00,000 people were reported in the mentioned region. According to the journal of Gastroenterology’s on Inflammatory Bowel Disease (IBD) in 2017, around 1.6 million patient in the U.S were suffering from of IBD, out of which considerable section belongs to Crohn’s disease. Such high incidence of Crohn’s disease in the U.S is attributed to high genetic risk associated with this population. Crohn’s disease treatment market is lucrative, owing to chronic nature of disease that require long term therapy with up to 70% chances of relapse.
However, high cost associated with Crohn’s disease is a hindering the growth of market. Also, off patenting of biologic is restraining the growth of the market. Cadila healthcare launched biosimilar of Adalimumab in the U.S. market in 2014 at one fifth of cost of original brand Humira.
Crohn’s Disease Treatment Market Taxonomy
On the basis of drug class:
On the basis distribution channel:
According to a study published in Karger journal in November 2017, Asia Pacific economies such as India and China have high incidence and prevalence of Crohn’s disease due to factors such as diet, hygiene, and autoimmune response (Increased westernized living). China has high incidence of inflammatory bowel disease with 344 patients per 1, 00,000 population according to epidemiological study published in 2013 in the Gastroenterology Journal. . First line therapy such as amino salicylate and corticosteroids are preferred choice in this region and expected to fuel market here due to low cost associated with these therapies. However, unmet requirements of patient for treatment of Crohn’s disease is restraining the growth of market in this region. For instance, many patients are non-respondent to immunomodulaters, corticosteroids therapy who can be further shifted to biologic product to treat Crohn’s disease, so this market may provide lucrative opportunity for growth. Major pharmaceutical companies are investing in research and development activities to develop novel molecule for treatment of Crohn’s disease. In 2016, Janessan got FDA approval for new biologic drug Ustekinumab (Stelara) to treat Crohn’s disease. Introduction of biosimilar to targets tumor necrosis factor-alpha such as Infliximab, adalimumab, Certolizumab are fueling the growth of Crohn’s disease treatment market. Merck & Co. Inc. recently launched biosimilar version of Janessan’s Remicade (Infliximab) named Reneflexis Pfizer in December 2017, which got FDA approval for biosimilar version of Remicade called Ixifi. These products are expected to boost the growth of Crohns’ disease treatment market.
Key players operating in global Crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Allergan Inc., Bayer AG, Bristol-Myers Squibb, Pfizer Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Novartis International AG, Sanofi, and Takeda Pharmaceutical Company Limited.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.